
|Videos|June 17, 2014
What's New in Metastatic Breast Cancer Research
Nancy Lin, MD, of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, discusses the differences between breast cancer subtypes and looks at recent drug approvals and research directions for the future.
Advertisement
Nancy Lin, MD, of the Susan F. Smith Center for Women’s Cancers at the Dana Farber Cancer Institute, discusses the differences between breast cancer subtypes and looks at recent drug approvals and research directions for the future.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
4
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
5

















































































































































































































